~~WHAT IS~~ CLAIM~~ED IS~~:

1. Use of Lipoplatin for the preparation of a first dose of a medicament and a second dose of a medicament for ~~A~~a method for inhibiting the growth of a solid tumor or treating cancer in a patient, wherein the method comprises~~ing~~ administering to the patient an effective amount of Lipoplatin monotherapy in ~~a~~ the first dose and an effective amount of Lipoplatin monotherapy in the second dose, thereby inhibiting the growth of the solid tumor or treating cancer.

2. The ~~method~~ use of claim 1, wherein the first dose is administered on day 1 and the second dose is administered between 12 to 36 hours after completion of the first dose.

3. The ~~method~~ use of claim 1 or 2, wherein the first dose and the second dose are repeated two or more times, at intervals comprising 4 to 35 days there between.

4. The ~~method~~ use of any one of claims 1~~-~~to 3, wherein the first dose comprises from about 100 mg/m^2 to 300 mg/m^2 Lipoplatin and the second dose comprises from about 100 mg/m^2 to 300 mg/m^2 Lipoplatin.

5. The ~~method~~ use of any one of claims 1~~-~~to 3, wherein the first dose comprises from about 150 mg/m^2 to 250 mg/m^2 Lipoplatin and the second dose ~~are~~ comprises from about 150 mg/m^2 to 250 mg/m^2 Lipoplatin.

6. The ~~method~~ use of any one of claims 1~~-~~to 5, wherein the solid tumor or cancer comprises metastatic or non-metastatic lung cancer, non-small cell lung cancer (NSCLC), breast cancer, Triple-negative breast cancer, gastric cancer, head and neck cancer, colon cancer, colorectal cancer, rectal cancer, pancreatic cancer, mesothelioma, brain cancer, (glioblastoma multiform or metastases) or ovarian cancer.

7. The~~ method~~ use of any one of claims 1 to 6, wherein the method comprises first line, second line or third line therapy.

8. The ~~method~~ use of any one of claims 1 to 6, wherein the patient has previously been treated with radiotherapy or oxaliplatin.

9. The use~~method~~ of any one of claims 1 to 6, wherein the first dose and/or second dose is administered intravenously or by inhalation therapy.

10. The ~~method~~ use of claim 6, wherein Lipoplatin is administered intraveneously.

11. The ~~method~~ use of any preceding claim wherein the method is repeated with an interval of about 21 days to 35 days there between.

12. The ~~method~~ use of any preceding claim wherein the method is repeated with an interval of about 26 days to 30 days there between.

13. The ~~method~~ use of any preceding claim, wherein the method further comprises~~ing~~ administering an effective amount of a second chemotherapeutic agent.

14. The ~~method~~ use of claim 13, wherein the second therapeutic agent is one or more of oxaliplatin, paclitaxel, vinorelbine or gemcitabine.

15. Use of Lipoplatin for the preparation of a first dose of a medicament and a second dose of a medicament for ~~A~~a method for inhibiting the growth of a solid tumor or treating cancer in a patient, wherein the method comprises~~ing~~ administering a first dose of ~~Lipoplatin monotherapy, wherein the first dose comprises~~ about 200 mg/m^2 of Lipoplatin monotherapy and a second dose of about 200 mg/m^2 of Lipoplatin monotherapy about 24 hours after administration of the first dose, thereby inhibiting the growth of the tumor or treating the patient.

16. The use~~method~~ of claim 15, wherein the cancer is lung cancer.

17. The use~~method~~ of claim 15 or 16, wherein the first dose and/or second dose is for administerin~~ged~~ intravenously to the patient in a formulation comprising about 2 liters of a 5% Dextrose solution or saline.

18. The use~~method~~ of claims 15 to 17, wherein the method further comprises~~ing~~ one or more treatment cycles comprising repeating the first dose and the second dose ~~is~~ about every 14 days, after administration of the first dose.

19. The use~~method~~ of claim 18, wherein the one or more treatment cycles comprises at least 6 cycles of administration of the first dose and the second dose.

20. Use of Lipoplatin for the preparation of a first dose of a medicament and a second dose of a medicament for ~~A~~ a method for inhibiting the growth of a solid tumor or treating cancer in a patient, wherein the method comprises~~ing~~ administering a first dose of ~~Lipoplatin monotherapy, wherein the first dose comprises~~ about 200 mg/m^2 Lipoplatin monotherapy and a second dose of about 200 mg/m2 of Lipoplatin monotherapy about 4 weeks after administration of the first dose, thereby inhibiting the growth of the tumor or treating the patient.

21. The use~~method~~ of claim 20, wherein the first dose and/or second dose is for administering~~ed~~ intravenously to the patient in a formulation comprising about 2 liters of a 5% Dextrose solution or saline.

22. The use~~method~~ of claims 20 or 21, wherein the method further comprises~~ing~~ one or more treatment cycles comprising repeating the first dose and the second dose as a maintenance therapy for the patient for life or until disease progression of the cancer or solid tumor.

23. Use of Lipoplatin for the preparation of medicament for ~~A~~ a method for inhibiting the growth of a brain tumor or treating a brain tumor in a subject, wherein the method comprises~~ing~~ intra-arterial administration of an effective amount of Lipoplatin to the subject, thereby inhibiting the growth of the brain tumor or treating the brain tumor.

24. The ~~method~~ use of claim 23, wherein the brain tumor is a glioblastoma multiform tumor or a tumor that has metastasized to the brain from a primary tumors outside the brain.

25. The ~~method~~ use of claim 23 or 24, wherein the method further comprises~~ing~~ administering to the subject an effective amount of a one or more of a drug that enhances penetration and transport of Lipoplatin across the blood-brain-barrier (BBB), low dose radiation or oncothermia.

26. The ~~method~~ use of claim 25, wherein the drug that enhances penetration and transport of Lipoplatin is temozolomide.

27. The ~~method~~ use of claim 25, wherein the low dose radiation comprises one or more of an x-ray or a gamma knife.

28. A pharmaceutical Lipoplatin composition comprising an effective amount of Lipoplatin to provide a dose of from about 100 mg/m2 to about 300 mg/m2 to a subject in a pharmaceutically acceptable carrier.

29. The pharmaceutical composition of claim 28, further comprising an effective amount of a drug that enhances transport of the Lipoplatin across the blood brain barrier.

30. A kit comprising the composition of claim 28 or 29, and optionally instructions for performing the method ~~of~~ referred to in any one of claims 1 to 27.